Will CEO’s New Strategy Boost Roche’s Phase III Success?
Greater Emphasis On Phase II To Boost Chances
Six months after taking the reins, Thomas Schinecker has unveiled a new approach aimed at preserving Roche’s 'R&D diversity' while cutting costly Phase III failures.
You may also be interested in...
A Phase I study showed better response and survival rates than Amgen’s Lumakras and Mirati’s Krazati, but investigators said confirmation from larger trials is needed.
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
The Swiss behemoth’s top five growth drivers – Vabysmo, Ocrevus, Hemlibra, Evrysdi and Phesgo – are selling well and softening the loss in earnings from products that boomed during COVID-19.